SCHEMBL13020162

SCHEMBL13020162

CC1CCC(n2nc(-c3ccc(Cl)cc3)c3c(N)ncnc32)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 16/20 0.62
KDR P35968 16/20 0.62
ABL1 P00519 14/20 0.62
EGFR P00533 14/20 0.62
HCK P08631 14/20 0.62
PIK3CD O00329 14/20 0.62
PIK3CA P42336 14/20 0.62
PIK3CB P42338 14/20 0.62
PIK3CG P48736 14/20 0.62
PRKDC P78527 14/20 0.62
MTOR P42345 13/20 0.62
EPHB4 P54760 13/20 0.62
PI4KB Q9UBF8 8/20 0.62
BTK Q06187 4/20 0.60
LCK P06239 4/20 0.60
LYN P07948 2/20 0.60
CYP1A2 P05177 2/20 0.60
DAPK3 O43293 1/20 0.60
RIPK2 O43353 1/20 0.60
FYN P06241 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23997158 0.91 SRC (0.61) SRCKDRABL1EGFRHCK
SCHEMBL13019694 0.89 PIK3CD (0.72) SRCKDRABL1EGFRHCK
SCHEMBL13019691 0.89 PIK3CD (0.72) SRCKDRABL1EGFRHCK
SCHEMBL13019673 0.88 PIK3CD (0.71) SRCKDRABL1EGFRHCK
SCHEMBL22364031 0.88 BTK (0.65) SRCKDRABL1EGFRHCK
SCHEMBL13020181 0.87 BTK (0.72) SRCKDRABL1EGFRHCK
SCHEMBL13020215 0.86 ABL1 (0.68) SRCKDRABL1EGFRHCK
SCHEMBL3791532 0.85 SRC (0.61) SRCKDRABL1EGFRHCK
SCHEMBL13020127 0.84 EGFR (0.59) SRCKDRABL1EGFRHCK
SCHEMBL23997146 0.84 BTK (0.65) SRCKDRABL1EGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885KDR 4598/4885ABL1 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.